Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term immune response to RV001 vaccination in RhoVac-001 participants
2020-004705-31Phase 2Completed
- Sponsor
- RhoVac AB
- Start
- Jan 2021
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of onilcamotide in prostate cancer (PCa), sponsored by RhoVac AB. Primary endpoint: Immunological response. Started Jan 2021; status: completed.
02
Drugs
onilcamotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2020-004705-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004705-31.